Drug Survival of Biologics in Pediatric Patients with Hidradenitis Suppurativa seen at Duke, MGH and UMass Memorial Health
Duke University School of Medicine
Duke University School of Medicine
Overview
Hidradenitis Suppurativa (HS) is a debilitating and socially challenging chronic inflammatory skin condition that affects apocrine glands. Immune system dysregulation plays a key role in the development of HS which led to the use of biologic therapies to treat HS. Studies have shown the drug survival of biologics in patients with HS is significantly shorter compared to drug survival in other autoimmune diseases. A retrospective study using data from adult HS patients found that older age, longer disease duration, and surgery during treatment were associated with longer biologic survival. To our knowledge, biologic survival in pediatric HS patients has not been previously investigated. In this multicenter retrospective study, we assess whether biologic survival differs between pediatric and adult HS patients. We also evaluate what factors are predictive of biologic survival and lead to biologic cessation in pediatric HS patients and whether these factors differ from those in adult HS patients.
Status
This project was funded through a 2024 PeDRA Research Fellowship Grant and has resulted in one publication titled, Drug survival of adalimumab is superior to infliximab in pediatric patients with hidradenitis suppurativa, published in the Journal of the American Academy of Dermatology in 2025.
